Loading...
You are viewing a DELETED record.
This record information is displayed for reference purpose only and should be not used.
This document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Internationally Recognized Certificates of Compliance
(IRCC)
See amendment history for more information.
last updated: 05 Nov 2022
ABSCH-IRCC-IN-262291-1
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
India/NBA/Appl/9/INBA3202203561
Application in Form-III for seeking approval for the invention on “ An Antibody Fragment Based Antifungal Conjugate Selectively Targeting Candida " for obtaining IP rights in India, PCT and USA.
Indian Patent Application No.- 202021020768
19 Aug 2022
Yes
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
Confidential information
Organization:AbGenics LifeSciences Pvt. Ltd. (AbGenics)Private sector (business and industry)Kant Helix, 1st Floor, Tata Motors Ltd., Bhoir Colony Chinchwad,Pune, Maharashtra
411033, IndiaPhone: +919657040868,Fax:Email: info@abgenics.in,Website:
Confidential information
Yes
1. The user shall notify NBA within 60 days from the date of grant of IPR and also assignment or license of the IPR if any, to any person.
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be 0.2% on the annual gross ex-factory sale minus government taxes.
3. The user shall inform NBA about any commercialization made on the IP Rights.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon.
For obtaining IP Rights on the invention titled “ An Antibody Fragment Based Antifungal Conjugate Selectively Targeting Candida " in India, PCT and USA.
Bioresource:
Camelus dromedarius - Camel - Blood
Camelus dromedarius - Camel - Blood
Confidential information
- Commercial
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 3.0% of the fee received (in any form including the license / assignee fee) and 2.0% of the royalty amount received annually from the assignee/licensee.
2. In case the user assigns or transfers the IPR in whole or in part to any person, whether voluntarily or involuntarily, the user undertakes to attach this agreement as an appendix to the assignment instrument which shall be binding upon such person.
Unique identifier | Status | Date |
---|---|---|
ABSCH-IRCC-IN-262291-1 |
REVOKED
OLD VERSION
PUBLISHED
DELETED
|
Rita Khanna (rita.khanna@nic.in/110058)
05 Nov 2022 09:42 on 05 Nov 2022 09:42
|